PUBLIC DECLARATION OF INTEREST

Based on the template annexed to the French order provided under article R. 1451-1 of the Public Health Code

I, the undersigned .Mette Kalager.....

Acknowledge that I am aware of my obligation to declare all interests, whether direct or indirect, that I have now or have had in the past five years, with any business, establishment or body whose work, technology or products fall within scope of the public health and health safety activities of the French National Cancer Institute at which I currently hold positions or exercise duties, or any collegial body (or bodies), commission(s), board(s), or working group(s) to which I belong or have been asked to provide my expertise, or with the companies or consulting firms operating in the same sectors.

Article L. 1454-2 of the French Public Health Code "A fine of €30,000 per occurrence shall be imposed on the persons described in items I and II of Article L. 1451-1 and in Article L. 1452-3 who, acting under the conditions provided in said article, wilfully neglect to establish or amend a declaration of interest in order to update the data contained therein or provide false information that undermines the truthfulness of the declaration."

I am completing this form in my capacity as (multiple responses possible):

☐ an officer of the French National Cancer Institute: (specify positions held) .....
.....

☒ a member of or advisor to a board, a commission, a committee, or a working group within the French National Cancer Institute: (specify the name) .....
INTERNATIONAL SCIENTIFIC ADVISORY BOARD

☐ a person asked to provide expertise to the French National Cancer Institute: (specify the theme/name of the consultancy assignment):.....
.....
☐ other: (specify) …….....

The following is my number in the RPPS (Directory of Healthcare Professionals), if I am a healthcare professional:

I undertake to update my public declaration of interest [PDoI] whenever these interests change. I am required to verify my PDoI at minimum once per year even if there have been no changes.

It is my responsibility, upon my receipt of the agenda for each meeting in which I am invited to participate, or for such provision of expert advice as the French National Cancer Institute may wish to entrust to me, to ascertain whether the interests that I have declared or may arise are compatible with my attendance at all or part of such meeting, or my participation in such provision of expert advice. In the event of any incompatibility, it is my responsibility to advise the designated contact person at the French National Cancer Institute and, if appropriate, the chairperson of the meeting prior its starting. In the event of a conflict of interest, my presence may cause the decisions made or recommendations, references or opinions issued to be tainted, and render them null and void.

Date:
September 24, 2026

Under the provisions of law no. 78-17 of 6 January 1978 as amended on data processing, electronic information and civil liberties, you have the right to access and amend your personal data. You may exercise this right by sending an email to: servicejuridique@institutcancer.fr

The information collected above will be processed electronically, and your declaration (except for any statements not made public) will be published on the INCa website. INCa is responsible for processing it for the purpose of preventing conflicts of interest, by comparing any declared connections with the objectives of the proposed tasks to be performed within INCa or on its behalf.

1. Main Occupation(s), remunerated or voluntary, exercised currently and over the past 5 years, full time or part time

☐ **Employment**

Main Employer(s)	Employer's address and place of practice, if different	Position in the organisation	Specialty or discipline, if applicable	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
University of Oslo, Norway, Department of Health Management and Health Economics, University of Oslo, P.O. Box 1089 Blindern, 0317 Oslo		Professor	Medicine	Sept 2018	Ongoing
Clinical Effectiveness Research Group, University of Oslo and Oslo University Hospital, Norway		Head	Medicine	2015	Ongoing
Oslo University Hospital, Division of Surgery, Inflammatory Diseases and Transplantation, P.O. Box 4950 Nydalen, 0424 Oslo, Norway		Researcher		Jan 2014	Ongoing

☐ **Liberal profession**

Activity	Place of work	Specialty or discipline, if applicable	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*

☐ **Other** (volunteer work, work during retirement, etc.)

Activity	Place of work, if applicable	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*

2. Secondary occupation(s)

2.1. Participation in a decision-making body of a public or private organisation whose work, technology or products fall within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

This relates, in particular, to healthcare establishments, consultancy businesses and advisory board, professional bodies (learned societies, health networks, health workers' association) and associations, including patients' associations.

☒ **I have nothing to declare in this section**

Currently or in the last 5 years:

Organisation *(company, establishment, association)*	Position in the organisation	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
		☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			
		☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			
		☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			

2.2. Consultant, advisor or expert activity (or activities) performed for an organisation that falls within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

This section includes, in particular, activities as an advisor or representative, participation in an advisory board, a working group, audits or the drafting of articles or expert reports.

☒ **I have nothing to declare in this section**

Currently and in the last 5 years:

Organisation *(company, establishment, association)*	Mission	Subject (name of study, product, technology or therapeutic indication)	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
			☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			
			☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			
			☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			

2.3. Participation in scientific work and studies for public and/or private organisations that fall within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

2.3.1 Involvement in clinical or preclinical trials or epidemiological studies

This section should include mention of any involvement in the execution of non-clinical and preclinical trials or studies (methodological studies, analytical tests, chemical, pharmaceutical, biological, pharmacological or toxicological testing, etc.), or clinical studies, epidemiological studies, medico-economic studies and observational studies on clinical and prescribing practices (in the latter case, indicate the subject).

Membership in monitoring and follow-up committees for clinical trials must be declared in this section.

Persons acting as principal investigators in single-centre studies or as coordinators in national or international multicentre studies are considered "principal investigators." This definition does not include investigators in multicentre studies not acting in a coordinating role - even if they may be referred to elsewhere as "principals." For the purposes hereof they shall be referred to as "investigators."

☐ **I have nothing to declare in this section**

Currently and in the last 5 years:

Sponsoring organisation (*company, establishment, association*)	Funding organisation(s) (if other than the sponsor, and to the best of your knowledge)	Subject (name of study, product, technology or therapeutic indication)	For clinical or preclinical trials or studies, specify:	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
The Research Council of Norway		The Nordic-European Initiative on Colorectal Cancer (NordICC)	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ❒ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……		01.05.2009	31.12.2031
The Research Council of Norway		European Polyp Surveillance (EPoS)	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……		1.4.2014	31.12.2017
National programme for clinical therapy research in the specialist health service, KLINBEFORSK		Colonize: Transplantation of intestinal microbiota in primary Clostridoides difficile infections	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ❒ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……		2019	2024

-AMED (Japan Agency for Medical Research and Development), Olympus Inc., Cybernet System Corp		EndoBRAIN International: Artificial Intelligence Aided Digagnosis of Colorectal Polys during Colonoscopy	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ❒ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)		April 2019	2020
The Norwegian Cancer Association		I-Scan: Risk of colorectal cancer in inflammatory bowel disease	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ❒ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)		2015	2021
National programme for clinical therapy research in the specialist health service, KLINBEFORSK		Refit 2 : Microbiota therapy as treatment in irritable bowel syndrom	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ❒ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)		2021	Ongoing
The Research Council of Norway		SAR: Surveillance after Adenoma Removal	Type of study: ☐ Single-centre study ❒ Multicentre study Your role: ❒ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)		2014	Ongoing
The Research Council of Norway		The Rapid-Cycle Re-Implementation of TRAining Facilities in Norway (TRAiN)	Type of study: ☐ Single-centre study ☐ Multicentre study Your role: ❒ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)		May 2020	2022

EU Horizon Europe Framework Programme (HORIZON)		Optimising Colorectal Cancer Prevention through Personalised Treatment with Artificial Intelligence - OperA	Type of study: ☐ Single-centre study ☐ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… …… ……		Begun September 2022	August 2027

2.3.2 Other scientific work

☒ **I have nothing to declare in this section**

Currently and in the last 5 years:

Organisation (*company, establishment, association*)	Subject (name of study, product, technology or therapeutic indication)	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
		☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			
		☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……			
		☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)			

2.4. Drafting of article(s) and presentation(s) at congresses, conferences, symposia, various public meetings or training activities organised or financially supported by private companies or organisations that fall within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

Such drafting of article(s) and presentations must be declared when they have been compensated or have been provided coverage of expenses.

2.4.1 Drafting of article(s)

☒ **I have nothing to declare in this section**

Currently and in the last 5 years:

Private company or organisation *(society, association)*	Subject of article	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
		☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… ……			
		☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… ……			
		☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… ……			

2.4.2 Oral presentation(s)

☒ **I have nothing to declare in this section**

Currently and in the last 5 years:

Inviting private company or organisation (*society, association*)	Location and name of the meeting	Subject of presentation, name of concerned product	Coverage of expenses	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
			○ Yes ○ No	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……. ……. …..…			
			○ Yes ○ No	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……. ……. …..…			
			○ Yes ○ No	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) ……. ……. …..…			

2.5. Invention or possession of a patent or a product, process or other form of non-patented intellectual property related to the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

☒ **I have nothing to declare in this section**

Currently and in the last 5 years:

Nature of the work and name of the patent, product, etc.	Organisation issuing the patent or marketing the product, etc.	Share of profits	Compensation	Amount of indemnity (specify frequency if applicable)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
		○ Yes ○ No	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… …… ……			
		○ Yes ○ No	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… …… ……			
		○ Yes ○ No	☐ None ☐ To the declarant ☐ To an organisation of which you are a member or employee (specify) …… …… ……			

3. Management of activities which have received funding from a profit-making organisation whose business activities fall within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

The type of funding may be in the form of subsidies or agreements for studies or research, grants or sponsorship, payments in kind, in cash, equipment.
This relates in particular to chairpersons, treasurers and members of management boards and executive committees, including for associations and learned societies.

☒ **I have nothing to declare in this section**

Currently and in the last 5 years:

Body and activity for which the funding was provided	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*	Profit-making organisation providing the funding and amount contributed by each for the funder(s) with optional indication of the corresponding percentage of the body's budget

4. Financial holdings in the capital of a company whose business activities falls within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

In this section, declare any listed or non-listed securities, including shares, bonds or other equity instruments, owned in any relevant sector or company or any subsidiary or part-owned company thereof, to the best of your immediate and reasonable knowledge. Please state the name of the establishment, company or organisation, the type of securities held, and their amount in absolute values and in percentages of capital owned.

Mutual funds, unit trusts such as SICAV or open-end funds, for which the individual has no control of the management or composition of the fund, are excluded from the declaration.

☒ **I have nothing to declare in this section**

Currently:

Organisation concerned	Type of investment	Amount held in absolute value	Percentage of the organisation's capital

5.

6. Elected positions and mandates currently held

☐ **I have no elected positions or mandates to declare**

Elected office or term (specify constituency)	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*
Head of Research Board, Norwegian Medical Association Elected position	2021	present

7. Other connections likely to give rise to situations of conflict of interest

Declare only the indemnity received by the declarant.

Example: Invitation to a conference, with no presentation required, with travel/accommodation fees covered or indemnity paid

☒ **I have nothing to declare in this section**

Element or fact concerned	Comments	Start date *(day (optional) / month / year)*	End date *(day (optional) / month / year)*

8.